Vivos Therapeutics (VVOS) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free VVOS Stock Alerts $2.29 +0.03 (+1.33%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 8:28 AM | msn.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2024 Earnings Call TranscriptMay 15, 2024 | msn.comVivos Therapeutics GAAP EPS of -$1.63, revenue of $3.4MMay 15, 2024 | finance.yahoo.comVivos Therapeutics Inc (VVOS) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 14, 2024 | investorplace.comVVOS Stock Earnings: Vivos Therapeutics Reported Results for Q1 2024May 14, 2024 | proactiveinvestors.comVivos Therapeutics reports first quarter cost savings, launches revenue-generating initiativeMay 14, 2024 | globenewswire.comVivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational UpdateMay 14, 2024 | globenewswire.comVivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference CallMay 12, 2024 | americanbankingnews.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest UpdateApril 11, 2024 | proactiveinvestors.comVivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approvalApril 9, 2024 | finance.yahoo.comVivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical DevicesApril 9, 2024 | markets.businessinsider.comVivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral DevicesApril 9, 2024 | msn.comWhat's Going On With Vivos Therapeutics Stock?April 9, 2024 | msn.comMedicare to reimburse for Vivos CARE sleep apnea devicesApril 9, 2024 | proactiveinvestors.comVivos Therapeutics CARE oral medical devices approved for Medicare reimbursementApril 9, 2024 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Up 16% Today?April 9, 2024 | msn.comVivos Therapeutics files to sell 1.73M shares of common stock for holdersApril 9, 2024 | finance.yahoo.comVivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementApril 9, 2024 | globenewswire.comVivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementApril 1, 2024 | proactiveinvestors.comVivos Therapeutics highlights path to cash flow positivity after FDA clearanceMarch 31, 2024 | finance.yahoo.comVivos Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 30, 2024 | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | marketwatch.comVivos Therapeutics Shares Fall After Wider-Than-Expected 4Q LossMarch 28, 2024 | globenewswire.comVivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateMarch 28, 2024 | globenewswire.comVivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallFebruary 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS), Short Interest ReportFebruary 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS) Insider TradesFebruary 18, 2024 | investing.comVivos Therapeutics secures $4 million through warrant exerciseFebruary 15, 2024 | finance.yahoo.comVivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsFebruary 15, 2024 | proactiveinvestors.comVivos Therapeutics sees gross proceeds of $4M from exercise of warrantFebruary 12, 2024 | finance.yahoo.comVivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market DisruptionsFebruary 6, 2024 | finanznachrichten.deVivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesFebruary 6, 2024 | finance.yahoo.comVivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesJanuary 8, 2024 | finance.yahoo.comVivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSADecember 18, 2023 | marketbeat.comTrading was temporarily halted for "VVOS" at 02:12 PM with a stated reason of "LULD pause." Trading set to resume at 02:12 PM. December 11, 2023 | proactiveinvestors.comVivos Therapeutics announces women-led airway health eventDecember 11, 2023 | finance.yahoo.comVivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”December 4, 2023 | marketbeat.comBlack Swan: this small cap surged over 1000% last weekVivos Therapeutics experienced a rare 'black swan' event, surging over 1000% in a single day following breaking news, here's how to look at VVOS stock nowDecember 1, 2023 | proactiveinvestors.comVivos Therapeutics severe sleep apnea treatment’s a ‘breakthrough’, says CEONovember 30, 2023 | benzinga.comThinking about buying stock in Minim Inc, Walmart, Farfetch Ltd, Qualcomm, or Vivos Therapeutics Inc?November 30, 2023 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Down 35% Today?November 30, 2023 | msn.comPhilips shares slump as FDA says sleep product may overheatNovember 29, 2023 | proactiveinvestors.comVivos Therapeutics: Who is the medical device company creating frenzy in the markets?November 29, 2023 | marketbeat.comTrading was temporarily halted for "VVOS" at 03:11 PM with a stated reason of "LULD pause."November 29, 2023 | marketbeat.comTrading was temporarily halted for "VVOS" at 03:11 PM with a stated reason of "LULD pause." Trading set to resume at 03:11 PM. November 29, 2023 | marketbeat.comTrading was temporarily halted for "VVOS" at 03:11 PM with a stated reason of "LULD pause."November 29, 2023 | marketbeat.comTrading was temporarily halted for "VVOS" at 03:11 PM with a stated reason of "LULD pause."November 29, 2023 | marketbeat.comTrading was temporarily halted for "VVOS" at 03:11 PM with a stated reason of "LULD pause."November 29, 2023 | marketbeat.comTrading was temporarily halted for "VVOS" at 02:11 PM with a stated reason of "LULD pause."November 29, 2023 | proactiveinvestors.comVivos Therapeutics receives first ever FDA 510(k) clearance...Vivos Therapeutics receives first ever FDA 510(k) clearance for...November 29, 2023 | msn.comVivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearance Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Automatic Income (from home) (Ad)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part… Watch this short video VVOS Media Mentions By Week VVOS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VVOS News Sentiment▼0.380.42▲Average Medical News Sentiment VVOS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VVOS Articles This Week▼82▲VVOS Articles Average Week Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Intelligent Bio Solutions News Today ProSomnus News Today Avinger News Today NeuroMetrix News Today Plus Therapeutics News Today Vapotherm News Today Biotricity News Today Titan Medical News Today Venus Concept News Today Tenon Medical News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VVOS) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressMost important medical advance in 100 yearsThe Oxford ClubUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingNext President (Not Trump. Not Biden.)The Freeport Society41 banks launch ‘crypto dollar’Stansberry ResearchWhat’s Really Next for America…Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
